Загрузка...
Evidence to date: talazoparib in the treatment of breast cancer
Approximately 5–10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recent...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6612288/ https://ncbi.nlm.nih.gov/pubmed/31303769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S184971 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|